Why is Senores Pharma. falling/rising?

As of 17-Jul, Senores Pharmaceuticals Ltd's stock price is currently at 621.70, reflecting an increase of 6.75 or 1.1%. The stock has shown strong performance recently, with a 5.60% increase over the past week and a notable 16.21% rise over the past month, significantly outperforming the Sensex, which has seen a decline of 1.12% in the same week and a modest gain of 0.83% over the month. Today's performance indicates that Senores Pharmaceuticals is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bullish trend. However, there has been a concerning drop in investor participation, with delivery volume falling by 46.57% compared to the 5-day average. While the company boasts a low debt-to-equity ratio and impressive long-term growth in net sales and operating profit, there are concerns regarding its valuation and falling institutional investor participation, which may be contributing to a cautious outlook.
In the broader market context, Senores Pharmaceuticals has outperformed the benchmark Sensex in the short term, with a 1-week return of +5.60% compared to the Sensex's -1.12%. This indicates that the stock is gaining traction despite the overall market conditions. However, the decline in institutional investor stakes and the flat results projected for December 2024 may create headwinds for future performance. The stock's expensive valuation, highlighted by a price-to-book ratio of 3.6 and a relatively low return on equity of 7.4%, could also be factors that investors are weighing against its recent gains.